All Machine Learning (ML) articles – Page 4
-
ArticleThe future of CNS drug development: signs of real progress
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 1
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
-
ArticleWhat single cells are revealing about brain disorders
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
-
ArticleFixing drug discovery’s most persistent problem with AI
AI will not replace drug discovery, but it might finally fix one of its most frustrating bottlenecks. Read how a targeted approach to ADMET is cutting through the noise.
-
ArticleHow dual-targeting ADCs aim to tackle resistance
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
-
NewsVirtual cell model rankings just got a major upgrade
Shift Bioscience has published a new study introducing enhanced metrics and baselines for evaluating virtual cell models - boosting gene target discovery and accelerating its rejuvenation therapeutics pipeline.
-
ArticleMachine Learning and AI in Enhancing Image Analysis of 3D Samples
Want to understand the real impact of AI in 3D sample analysis? This episode cuts straight to how machine learning is accelerating research and overcoming current limitations.
-
ArticleFuture-proofing drug development with GenAI
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
-
News
How bowel cancer beats treatment - and how AI can stop it
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
-
ArticleThe AI model that is changing clinical trial design
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
-
ArticleThe biotech mapping thousands of hidden therapeutic clues
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
-
ArticleTranslating Promising Drug Candidates from Preclinical Screening to Clinical Trials
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
-
NewsTurning AI into a biological design engine
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
-
ArticleThe next phase of the multiomics evolution, powered by AI
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
-
ArticleFrom siloed data to breakthroughs: multimodal AI in drug discovery
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
-
ArticleStrategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
-
ArticleWhat SLAS 2025 really told us about drug discovery
Forget the buzzwords - SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems.
-
ArticleHow AI and LLMs are transforming drug discovery: part 2
As AI reshapes scientific work, two founders debate how best to build tools scientists can trust — should we embed expertise into the model or the team? From agent-powered labs to hypothesis-generating machines, the future of drug discovery is being reimagined right now.
-
ArticleAI at the forefront of age-related disease treatment
The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ageing biology and develop combination therapies targeting the root causes of age-related diseases, offering hope for better treatments and quality of ...
-
NewsK Navigator: an AI co-pilot transforming biomedical research
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.